Methods of Determining Regulator Parameters for Power System Dynamic Equivalents

In this paper, two novel methods are proposed for determining the regulator parameters in the construction of power system dynamic equivalents based on coherency. The methods are based on the idea that the governor of the equivalent generator should have the characteristics which are the sum of the characteristics of the governors of the generators belonging to the coherent groups. Also, AVR should have the average characteristics of the AVRs of the coherent generators. The indicial response or the frequency response is used as the representative characteristic, and the equivalent parameters are determined so as to approximate the above ideal characteristics. The methods are applied to the construction of a dynamic equivalent of a sample ten-machine system, and their validity is examined

14q12 translocation in a non-Burkitt lymphoma.

Chromosome analysis was performed on cells from a patient of null cell lymphoma, well-differentiated type. A 14q12 translocation was observed in all the banded cells. In addition, there were multiple chromosome abnormalities. This case will be useful in considering the significance of the 14q1(1-3) translocation in malignant lymphoma disease.</p

Immuno-chemotherapy of malignant lymphoma using OK-432, a streptococcal agent

Clinical trials of immuno-chemotherapy were conducted on malignant lymphoma patients. Patients during the period from 1972 through 1977 were allocated to two groups retrospectively according to the mode of treatment, i.e., chemotherapy alone (historical control group, 35 patients) and chemotherapy with OK-432 (treated group, 15 patients). Comparisons were made of the two groups, which were homogeneous with regard to induction chemotherapy, maintenance chemotherapy, stage and histologic type of disease. The treated group had a higher remission rate, and a longer remission duration and survival than the control groups, especially in patients with Hodgkin's disease but the difference was not statistically significant owing to the limited number of cases.</p

Prompt improvement of a pressure ulcer by the administration of high viscosity semi-solid nutrition via a nasogastric tube in a man with tuberculosis: a case report

INTRODUCTION: Semi-solid nutrition with high viscosity has the advantage of reducing gastroesophageal reflux and diarrhea and shortens the duration of administration compared with liquid nutrition. This is the first report describing the administration of semi-solid nutrition with high viscosity via a nasogastric tube, which achieved a remarkable improvement in the patient's nutritional state. CASE PRESENTATION: A 67-year-old man (mongoloid race, Japanese) with tuberculosis, a pressure ulcer and malnutrition was admitted to our hospital. He also had right hemiplegia, dysphagia and aphasia as sequelae of a cerebral hemorrhage. Before his admission, he had been treated at another hospital with 600 kcal/day of liquid nutrition via a nasogastric tube, which was insufficient and induced severe malnutrition. After he was admitted to our hospital, we increased the quantity of his liquid nutrition without success because of complications, specifically diarrhea and gastroesophageal reflux. As it was difficult to confirm whether or not he would accept gastrostomy feeding, we administered semi-solid nutrition with high viscosity (20,000 mPa x s) via a large-bore nasogastric tube (18 French). Soon after he was started on semi-solid nutrition, his pressure ulcer and malnutrition improved without diarrhea or complications accompanying the large-bore nasogastric tube. CONCLUSION: When patients have problems with liquid nutrition, such as diarrhea or gastroesophageal reflux, semi-solid nutrition via a nasogastric tube is a useful method of achieving improvements in nutritional state in a short period of time

Genetic Analyses of Elys Mutations in Drosophila Show Maternal-Effect Lethality and Interactions with Nucleoporin Genes

ELYS determines the subcellular localizations of Nucleoporins (Nups) during interphase and mitosis. We made loss-of-function mutations of Elys in Drosophila melanogaster and found that ELYS is dispensable for zygotic viability and male fertility but the maternal supply is necessary for embryonic development. Subsequent to fertilization, mitotic progression of the embryos produced by the mutant females is severely disrupted at the first cleavage division, accompanied by irregular behavior of mitotic centrosomes. The Nup160 introgression from D. simulans shows close resemblance to that of the Elys mutations, suggesting a common role for those proteins in the first cleavage division. Our genetic experiments indicated critical interactions between ELYS and three Nup107–160 subcomplex components; hemizygotes of either Nup37, Nup96 or Nup160 were lethal in the genetic background of the Elys mutation. Not only Nup96 and Nup160 but also Nup37 of D. simulans behave as recessive hybrid incompatibility genes with D. melanogaster. An evolutionary analysis indicated positive natural selection in the ELYS-like domain of ELYS. Here we propose that genetic incompatibility between Elys and Nups may lead to reproductive isolation between D. melanogaster and D. simulans, although direct evidence is necessary

Combination chemotherapy of advanced non-Hodgkin's lymphoma with adriamycin, vincristine, ifosfamide and prednisolone (AVIP): a preliminary report

Eighteen patients with advanced non-Hodgkin's lymphoma other than the diffuse histiocytic type were treated with a combination of adriamycin, vincristine, ifosfamide and prednisolone (AVIP). The objective response rate was 83% (15/18); 61% (11/18) achieved complete remission. The median duration of complete remission was 11 months ranging from 2 to 39+ months. Eleven of the 18 patients are still alive during the median follow-up time of 13 months. The median survival was 14+ months for complete responders, and 9.5 months for partial and nonresponders. A myelosuppressive toxicity was well tolerated. AVIP offers some hope as treatment of advanced non-Hodgkin's lymphoma.</p

Studies on treatment of malignant lymphoma Part 2. Importance of bone marrow biopsy in the treatment of malignant lymphoma

One hundred and thirty-one patients with malignant lymphoma, including 84 patients without prior therapy, underwent Jamshidi needle bone marrow biopsy and bone marrow aspiration simultaneously. At the time of diagnosis, 20 (28%) of 71 patients with non-Hodgkin's lymphoma had bone marrow involvement, and the incidence of bone marrow involvement was higher in the diffuse medium-sized cell subtype than in the diffuse large cell subtype (42% vs. 13%, p<0.05). Thirty-one patients with non-Hodgkin's lymphoma had stage Ⅳ disease at the time of diagnosis. Among these, 20 (65%) had the disease in bone marrow which was the most frequent site of stage Ⅳ disease. Furthermore, 1 (13%) of 8 patients with stage I, 3 (19%) of 16 patients with stage Ⅱ and 5 (20%) of 25 patients with stage Ⅲ had a change of stage as a result of positive bone marrow examination. Non-Hodgkin's lymphoma patients with bone marrow involvement poorly responded to chemotherapy and had short survival time as compared to those without bone marrow involvement. During the course of therapy, 23 patients were found to have bone marrow involvement, and in 2 of these patients, bone marrow involvement was the only evidence of the disease. Comparison of bone marrow biopsy and simultaneously performed bone marrow aspiration showed that the biopsy more often gave a positive result than did the aspiration (84% vs. 42%). These results indicate that Jamshidi needle bone marrow biopsy is useful for accurate staging, planning therapy and evaluation of prognosis at the time of diagnosis as well as detecting the extralymphatic spread or relapse after the course of therapy in patients with malignant lymphoma

Studies on treatment of malignant lymphoma Part 1. Combination of adriamycin, vincristine, ifosfamide and prednisolone (AVIP) for malignant lymphomas refractory to conventional chemotherapy

Fifty-seven patients with advanced malignant lymphoma, who had failed to achieve complete remission or relapsed after conventional combination chemotherapy, were treated with a combination of adriamycin, vincristine, ifosfamide and prednisolone (AVIP). Twenty-five patients were given relatively low doses of adriamycin (0.5mg/kg), vincristine (0.025mg/kg), and ifosfamide (25mg/kg) at 7-day intervals (Regimen I), and the remaining 32 patients were given relatively high doses of these drugs (1.2mg/kg of adriamycin, 50mg/kg of ifosfamide and 0.03mg/kg of vincristine) at 21-day intervals (Regimen Ⅱ). Among 8 patients with Hodgkin's disease, 7 (88%) achieved objective remission including 4 (50%) complete remissions, and 3 complete respondors remain disease free in a follow-up from 44 months to 89 months. The overall median survival was more than 50 months, ranging from 12 months to more than 90 months. Among 49 patients with non-Hodgkin's lymphoma, 32 (65%) achieved objective remission including 15 (31%) complete remissions. The median duration of complete remission was 8 months, and 3 complete respondors remain disease free at 13, 36 and 90 months, respectively. The overall median survival was 8 months, ranging from 2 months to more than 91 months. The diffuse large cell type was the most frequent in non-Hodgkin's lymphoma. Among 27 patients with this histologic type, 17(63%) had objective remission including 7 (26%) complete remissions. The median duration of complete remission and the median survival were 11 months and 8 months, respectively. There were no significant differences in the therapeutic results of Regimen I and Regimen Ⅱ, although the latter showed a slightly higher response rate and longer duration of complete remission in non-Hodgkin's lymphoma. Reversible bone marrow toxicity was the major toxic reaction, but both regimens were well tolerated. These results indicate that a combination of AVIP is useful for treatment of malignant lymphomas refractory to conventional chemotherapy

対側の耳下腺および顎下腺を侵襲した悪性リンパ腫

A 75-year-old male was pointed out the right submandibular swelling followed by the left pre-auricular swelling, about half-year apart. Parenchyma of the left parotid gland was infiltrated by lymphoid growth, and the right submaxillary gland had a discrete lymphoid growth at a pole of the gland. Inside and outside these lymphoid growths, lymphocytes infiltrated between ducts, acini, adipose tissue, blood vessels and nerves. Patho-immunologically, the case was a follicular lymphoma of medium-sized (or small cleaved) cell type with no cytoplasmic immunoglobulin production, although a B-cell type of the malignant lymphoma was suggested because of a prominent nodular pattern. The patient has been in a complete remission for six months subsequent to chemotherapy. The major literature concerning malignant lymphoma primarily in parotid or submaxillary gland reported since 1959 was reviewed. The criteria for possible primary malignant lymphoma of the salivary gland, its pathogenesis and its differential diagnosis from other lymphoid and epithelial lesions were discussed